I-Vitamin K2 iyilungu lomndeni we- vitamin K , igumbi lezakhi ezibandakanya ukugaya igazi nokulondoloza impilo yethambo. Etholakala ngokwemvelo ezidlweni, ama-cheeses namaqanda, i-vitamin K2 (ebizwa nangokuthi i-menaquinone) nayo yenziwe ngamabhaktheriya. Ngaphezu kwalokho, abantu abaningi bathatha i-vitamin K2 efomini lokufaka isicelo.
Ukusetshenziswa
Ngokwelashwa okunye, abagqugquzeli bathi i-vitamin K2 ingasiza ngezinkinga zempilo eziningana, kufaka phakathi isifo senhliziyo nokuguqulwa kwamathambo.
Ngaphezu kwalokho, kuthiwa i-vitamin K2 ivikela ezinye izinhlobo zomdlavuza.
Izinzuzo zezeMpilo
Nakhu ukubuka okunye okufundwayo okufundwayo ekutheni izinzuzo zezempilo zika vithamini K2:
1) Izifo Zenhliziyo
Ucwaningo oluthile lubonisa ukuthi ukudla okunamandla kwe-vitamin K2 kunganciphisa ingozi yesifo senhliziyo. Esifundweni sika-2004 esivela kuyi- Journal of Nutrition , isibonelo, abacwaningi bahlaziya ukudla okune-vitamin K1 kanye ne-vitamin K2 phakathi kwabantu abangu-4 807 futhi bathola ukuthi labo abanesidumbu esiphezulu sawo wonke uhlobo lwe-vitamin K babenengozini ephansi kakhulu ye-coronary disease kanye ne-atherosclerosis. Ngaphezu kwalokho, amalungu okutadisha ne-vitamin K2 aphezulu kakhulu amathuba okufa ngesifo senhliziyo.
Ngaphezu kwalokho, ukubuyekezwa kokucwaninga kuka-2010 okushicilelwe emaphepheni okuthiwa i- Maturitas bathole ukuthi i-vitamin K2 ingasiza ekuvikeleni ngokumelene nezifo ze-cardio-metabolic (njengezifo zenhliziyo, uhlobo lwesifo sikashukela sesibili, nesifo se-metabolic syndrome).
Ekuhlaziyweni kwabo kwezifundo ezinhlanu kusetshenziswa i-vitamin K kanye nesifo se-cardio-metabolic, abalobi be-review babuye babone ukuthi i-vitamin K1 ingase ingavikeli ekuhluphekeni okunjalo.
2) I-Bone Health
Kunobunye ubufakazi bokuthi i-K2 ingathuthukisa impilo ye-bone futhi inciphise ingozi ye-osteoporosis. Ngombiko ka-2004 ovela ku- Current Pharmaceutical Design , ososayensi baqaphile ucwaningo olutholakalayo olwenziwe nge-vitamin K2 kanye ne-osteoporosis.
Imiphumela yabonisa ukuthi i-vitamin K2 ingashukumisa ukuthambo kwamathambo futhi igweme ukuwohloka kwethambo elihlobene nobudala. I-Vitamin K2 ibuye ibonakale isondeza isibindi samaminerali futhi igweme ama-osteoporotic fractures kuziguli ezine-osteoporosis ehlobene nobudala.
Ekubuyekezeni okucwaninga kamuva kwamanje okushicilelwe ku- Current Drug Safety , abacwaningi bathola ukuthi ukuhlanganisa i-vitamin K2 ne-bisphosphonate (isigaba semithi evikela ukulahlekelwa kwethambo mass) kungasiza ekuvimbeleni ukuhlukana kwamabhinqa ase-postmenopausal abane-osteoporosis ne-vitamin K ukuntuleka.
3) Igciwane
Ucwaningo lokuqala lubonisa ukuthi i-vitamin K2 ingasiza ekwelapheni ezinye izinhlobo zomdlavuza. Ngokwesibonelo, ngo-2003, ucwaningo lwe-tube-test lwe- International Journal of Oncology , abacwaningi bathola ukuthi i-vitamin K2 ingasiza ekukhuthazeni ukufa kwamangqamuzana omdlavuza wamaphaphu.
I-Vitamin K1 vs. Vitamin K2
I-Vitamin K1 (eyaziwa nangokuthi i-phylloquinone) yindlela yevithamini K etholakala ezitshalweni. I-Vitamin K iyatholakala futhi nge-vitamin K3 (eyaziwa ngokuthi i-menaphthone noma i-menadione).
Ngokusho kweNational Institutes of Health, i-vitamin K1 yindlela esheshayo, esebenzayo, futhi ephumelelayo kwezinye izimo kunezinye izinhlobo ze-vitamin K. Noma kunjalo, ucwaningo oluthile lubonisa ukuthi ukungenisa i-vitamin K2 kunganikeza izinzuzo ezithile zezempilo.
Amapulangwe
Ukuthatha amanani amaningi kunoma yiluphi uhlobo lwe-vitamin K kungalimaza abesifazane abakhulelwe nabancelisayo, iziguli ezithola ukwelashwa kwe-dialysis ngenxa yesifo sezinso, kanye nabantu abanezinkinga zokuqeda izifo ezibangelwa isifo esinamandla esibindi. Ngaphezu kwalokho, i-vitamin K ingasebenzisana nezinye izithako (kufaka phakathi i-coenzyme Q10 ne- vitamin E ).
Indlela Yokusebenzisa Ngayo Impilo
Okwamanje ayikho izincomo ezandisiwe zokungezwa nge-vitamin K. Nakuba i-vitamin K2 ingasiza ngezinkinga ezithile zempilo, ukuziphatha ngokweqile nge-vitamin K2 nokugwema ukunakekelwa okujwayelekile kungase kube nemiphumela emibi yempilo.
Ngaphambi kokuba uqale ukusebenzisa i-vitamin K2, khuluma nodokotela wakho ukuze uthole isilinganiso esiphephile nesisebenzayo.
> Imithombo:
> Gast GC, de Roos NM, Sluijs I, Bots ML, Beulens JW, Geleijnse JM, Witteman JC, Grobbee DE, Peeters PH, van der Schouw YT. "I-Acne Menaquinone Ephakeme Iyanciphisa Isigameko Sezifo Zezinhliziyo ZaseCoronary." I-Nutr Metab I-Cardiovasc Dis. 2009 Sep; 19 (7): 504-10. Epub 2009 Jan 28.
> Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, van der Meer IM, Hofman A, Witteman JC. "Ukudla Kwemithi Ye-Menaquinone Kuhlobene Neengozi Enciphisa Ingculazi Yenhliziyo Yomzimba: i-Rotterdam Study." J Nutriti. 2004 Nov; 134 (11): 3100-5.
> Iwamoto J, Takeda T, Sato Y. "Imiphumela ye-Vitamin K2 ekufoqeni kwe-osteoporosis." I-Curr Pharm Des. 2004; 10 (21): 2557-76.
> Iwamoto J, Takeda T, Sato Y. "Indima ye-Vitamin K2 ekuPhilweni kwe-Postmenopausal Osteoporosis." I-Curr Drug Saf. 2006 Jan; 1 (1): 87-97.
> I-Koitaya N, Ezaki J, Nishimuta M, Yamauchi J, Hashizume E, Morishita K, Miyachi M, Sasaki S, Ishimi Y. "Imiphumela ye-Low Dose Vitamin K2 (MK-4) Ukwengezwa kwi-Bio-indices kuma-Japanese Women Postmenopausal. " J Nutr Sci Vitaminol (Tokyo). 2009 Feb; 55 (1): 15-21.
> Rees K, Guraewal S, Wong YL, Majanbu DL, Mavrodaris A, Eyabangalisa S, Kandala NB, Clarke A, Franco OH. "Ingabe ukusetshenziswa kweVitamin K Okuhlobene Ne-Cardio-Metabolic Disorders? Ukubukeza Okuhlelekile." Maturitas. 2010 Oct; 67 (2): 121-8. Epub 2010 Jun 17.
> Yoshida T, Miyazawa K, Kasuga I, Yokoyama T, Minemura K, Ustumi K, Aoshima M, Ohyashiki K. "Ukukhishwa Kwama-apoptosis we-Vitamin K2 Emkhakheni Wama-Lung Carcinoma: I-Possibility of Vitamin k2 Therapy for Cancer Lung." Int J Oncol. 2003 Sep; 23 (3): 627-32.